2025-10-09 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the provided information. The report is structured to provide a clear and concise overview of the company's performance and future prospects.

**Report: Natera Inc. (NTRA) Analysis**

Natera Inc. is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.

**1. Performance vs. S&P 500 (VOO)**

*   **NTRA Cumulative Return:** 77.87%
*   **VOO Cumulative Return:** 99.88%
*   **Absolute Divergence:** -25.8
*   **Relative Divergence:** 23.8 (Indicates NTRA is in the lower quartile compared to its historical performance relative to VOO)

**Analysis:** NTRA has underperformed the S&P 500 by -25.8% over the period. The relative divergence suggests that this underperformance is significant compared to its historical trends.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD  | Alpha  | Beta   | Cap(B) |
| :----------- | :------ | :----- | :------- | :----- | :------ |
| 2015-2017  | -10.0% | 70.1% | -34.0% | -0.2 | 1.2  |
| 2016-2018  | 22.0%  | 80.0% | 6.0%   | 0.1  | 1.9  |
| 2017-2019  | 50.0%  | 80.0% | 28.0%  | 1.0  | 4.6  |
| 2018-2020  | 186.0% | 80.5% | 163.0% | 1.1  | 13.7 |
| 2019-2021  | 96.0%  | 80.5% | 49.0%  | 1.6  | 12.8 |
| 2020-2022  | -77.0% | 80.5% | -76.0% | 0.1  | 5.5  |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1 | 8.6  |
| 2022-2024  | 8.0%   | 76.6% | -13.0% | -1.2 | 21.7 |
| 2023-2025  | 105.0% | 76.6% | 41.0%  | 0.1  | 23.6 |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Highly volatile, with significant gains in some periods and substantial losses in others, indicating a high-risk investment.
*   **MDD (Maximum Drawdown):** Consistently high (around 80%), confirming the volatile nature of the stock.
*   **Alpha:** Varies significantly, indicating periods of both outperformance and underperformance relative to the market. Recent years show negative alpha, suggesting underperformance.
*   **Beta:** Fluctuates, suggesting varying sensitivity to market movements. Some periods show a negative beta, indicating the stock moves inversely to the market.
*   **Cap(B):** Market capitalization varies over time.

**2. Recent Price Action**

*   **Current Price:** 172.09
*   **Previous Close:** 168.53
*   **Change:** 2.11 (A notable positive change from the previous close.)
*   **5-day Moving Average:** 167.71
*   **20-day Moving Average:** 169.25
*   **60-day Moving Average:** 158.71

**Analysis:** The stock price is currently above all three moving averages, suggesting a short-term upward trend. The recent price increase of 2.11 indicates positive momentum.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 40.28 (Neither overbought nor oversold)
*   **PPO:** -0.08 (Slightly bearish momentum)
*   **Hybrid Signal:** Buy 100% of cash (6 shares - Very Safe - MRI:0.90). Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **Delta Previous Relative Divergence:** 0.9 (+): Short-term increase
*   **Expected Return:** -151.9% (Significant underperformance relative to the S&P 500 over a 2-year investment horizon)

**Analysis:** Despite the medium investment recommendation from the MRI, the negative PPO and the significantly negative expected return suggest caution. The recent increase in relative divergence is a positive sign, but needs to be viewed in the context of the overall negative outlook. The hybrid signal indicates a buy recommendation and advise for monthly investment, but the conflicting negative expected return needs further investigation. The considerable positive change suggests that the price is experiencing a rebound.

**4. Recent News & Significant Events**

*   **Positive:**
    *   Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
    *   Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
    *   Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging
*   **Neutral/Mixed:**
    *   2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
    *   Exploring 3 High Growth Tech Stocks In The US Market

**Analysis:** The recent news is generally positive, focusing on the progress and validation of Natera's testing products. This could be contributing to the recent price increase.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.53 (~Buy)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 193.21 / 235.00 / 37.00

**Analysis:** Analysts generally have a positive outlook on NTRA, with a "Buy" consensus and a significant average target price of $193.21, suggesting considerable upside potential. However, the wide range between high and low target prices ($37.00 - $235.00) indicates uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출     |
| :----------- | :----- | :------- |
| 2025-08-08 | -0.74 | 0.55 B$ |
| 2025-05-09 | -0.5  | 0.50 B$ |
| 2024-11-12 | -0.26 | 0.44 B$ |
| 2024-08-09 | -0.3  | 0.41 B$ |
| 2025-08-08 | -0.3  | 0.41 B$ |

**Analysis:** Natera is currently not profitable, as indicated by the negative EPS figures. However, revenue is showing a positive trend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------- | :-------------- |
| 2025-06-30 | $0.55B   | 63.41%          |
| 2025-03-31 | $0.50B   | 63.12%          |
| 2024-12-31 | $0.48B   | 62.94%          |
| 2024-09-30 | $0.44B   | 61.79%          |
| 2024-06-30 | $0.41B   | 58.83%          |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
| :--------- | :-------- | :------- |
| 2025-06-30 | $1.25B   | -8.10% |
| 2025-03-31 | $1.24B   | -5.40% |
| 2024-12-31 | $1.20B   | -4.50% |
| 2024-09-30 | $0.88B   | -3.60% |
| 2024-06-30 | $0.84B   | -4.48% |

**Analysis:**

*   **Revenue:** Shows consistent growth over the past several quarters.
*   **Profit Margin:** High and improving, indicating strong pricing power and cost management.
*   **Equity:** Increasing, suggesting the company is strengthening its financial position.
*   **ROE (Return on Equity):** Negative, due to the company's current lack of profitability. However, it is trending upwards, suggesting potential for improvement.

**7. Overall Analysis & Recommendation**

Natera Inc. (NTRA) is a company with high growth potential in the genetic testing and diagnostics industry. Recent news highlights advancements and validation of its products, which have likely contributed to recent positive price movements. Analysts hold a generally favorable view of the stock.

However, there are several factors that warrant caution:

*   **Underperformance:** NTRA has significantly underperformed the S&P 500 and has shown high volatility.
*   **Profitability:** The company is currently not profitable, as evidenced by negative EPS and ROE.
*   **Expected Return:** A significantly negative expected return suggests caution and indicates a long-term bearish outlook from the model.
*   **Hybrid Signal Conflict:** The hybrid signal suggest to buy but the negative expected return needs further investigation.

**Recommendation:** Given the conflicting signals, a neutral position is recommended. Investors should closely monitor the company's progress towards profitability and carefully consider their risk tolerance before investing in NTRA. Further research into the reasons behind the negative expected return is warranted.
